Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | MAP3K5 | Q99683 | 11/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | WNT1 | P04628 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.36 |
| ▸ | CLK3 | P49761 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20162127 | 0.89 | TAS2R8 (0.47) | TAS2R8HDAC6HDAC8MAP3K5WNT1 | |
| SCHEMBL20364365 | 0.89 | MAP3K5 (0.36) | ESR2TAS2R8NR1H2MAP3K5MTOR | |
| SCHEMBL20364364 | 0.86 | ESR2 (0.53) | ESR2TAS2R8NR1H2HDAC6HDAC8 | |
| SCHEMBL20364363 | 0.83 | ESR2 (0.48) | ESR2TAS2R8NR1H2HDAC6HDAC8 | |
| SCHEMBL20364362 | 0.82 | ESR2 (0.55) | ESR2TAS2R8NR1H2HDAC6HDAC8 | |
| SCHEMBL20364337 | 0.81 | ESR2 (0.46) | ESR2TAS2R8NR1H2HDAC6HDAC8 | |
| SCHEMBL20364347 | 0.80 | TAS2R8 (0.49) | ESR2TAS2R8NR1H2HDAC6HDAC8 | |
| SCHEMBL20170243 | 0.79 | ESR2 (0.47) | ESR2TAS2R8NR1H2MAP3K5 | |
| SCHEMBL20367121 | 0.78 | ABCB1 (0.44) | ESR2TAS2R8NR1H2MAP3K5 | |
| SCHEMBL20162134 | 0.78 | TAS2R8 (0.37) | TAS2R8MAP3K5WNT1GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | NR0B1, NR2E1, NR0B2 | ESR2 620/4885TAS2R8 2479/4885NR1H2 313/4885 |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | NR0B1, NR2E1, NR0B2 | ESR2 620/4885TAS2R8 2479/4885NR1H2 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.